DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
2024 · Nature Communications · 76 citations
https://doi.org/10.1038/s41467-023-44237-4
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
971
Citations
8
h-index
8
i10-index
Xiaoyou Liang is an academic researcher from Novartis (United States). The author has contributed to research in topics: Ubiquitin and proteasome pathways & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 8, co-authored 9 publications.
https://doi.org/10.1038/s41467-023-44237-4
https://doi.org/10.1038/s41467-024-51317-6
Click to start Chat